Homepage Top Section1

Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement

The research team used a single low dose of Novartis’ leukemia drug Tasigna (nilotinib) in a phase II clinical trial in Parkinson’s disease patients. The researchers claimed that

According to Seres Therapeutics, the partners will research to assess microbiome-based approaches as a predictor for which cancer immunotherapies get the best response from patients. In addition, the

Oncternal Therapeutics will be the name of the combined company, which will engage in the development of potential first-in-class therapeutic candidates for cancers. As per terms of the

The 30-week long trial, dubbed Sustain 9, assessed the efficacy and safety of Ozempic injection 1.0 mg in combination with the SGLT-2 inhibitors against placebo. The drug was

Also known as RPL554, ensifentrine, is being investigated as an inhaled dual inhibitor of the phosphodiesterase 3 and 4 enzymes and is designed to have bronchodilator and anti-inflammatory

The phase IIIb trial compared Feraccru against Ferinject in 242 inflammatory bowel disease (IBD) patients whose iron deficiency anaemia (IDA) and haemoglobin (Hb) measurements are as low as

Maze Therapeutics has secured an initial investment commitment of $191m, led by Third Rock Ventures and ARCH Venture Partners. GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and

The expanded Farxiga and Xigduo XR labels have been approved to treat patients with T2D and moderate renal impairment, which is a chronic kidney disease with an estimated